Synergistic effects were shown when SHP2 inhibitors were combined with vemurafenib, and the combination overcame neuroblastoma’s resistance to SHP2 inhibition in vitro and in vivo [72]. This evidence concerns the gene PTPN11 and neuroblastoma.